
GLP-1 Weight-Loss Drugs Turn Office Small Talk Into HR Dilemmas
GLP-1 weight-loss drugs like Ozempic are turning casual office chatter into delicate HR and policy debates, as coworkers question body changes, while employers grapple with potential premium impacts and the ethics of sharing medical information. Even though individuals can discuss their own treatment, the conversations raise concerns about privacy, stigma, and fairness, leaving benefits teams balancing empathy with economics in a murky, evolving workplace landscape.




